RARE vs SDGR · rev $560.2M vs rev $255.9M
Ultragenyx (RARE) versus Schrodinger Inc (SDGR) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Schrodinger Inc (SDGR) is a health information services company listed on NASDAQ.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported SDGR revenue for 2025-12-31 was $255.9M. Net income was -$103.3M. Revenue was up 23.3% from 2024-12-31 to 2025-12-31. SDGR currently screens at market cap $1.16B.
RARE currently screens at market cap $2.79B. SDGR currently screens at market cap $1.16B.
Not investment advice. Open the RARE and SDGR stock pages for the full models.
Not investment advice.